|
Profit before tax declined 23.05% year on year to Rs 154.49 crore in the quarter ended 31 December 2022.
On the segmental front, API revenue was Rs 326 crore (up 65% YoY). In the Formulations business, US revenue was Rs 432 crore (up 10% YoY), India revenue was Rs 545 crore (up 12% YoY) and Ex-US revenue was Rs 206 crore (up 7% YoY).
EBIDTA fell by 10% to Rs 236 crore in Q3 FY23 from Rs 261 crore in Q3 FY22. EBIDTA margin slipped to 16% in Q3 FY23 as against 21% in Q3 FY22.
R&D expenses aggregated to Rs 157 crore during the quarter while Capex spend stood at Rs 113 crore.
Pranav Amin, managing director, Alembic Pharmaceuticals, said: “The company witnessed topline growth across all the verticals. In particular, the API business outperformed with a 65% growth during the quarter.”
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.
The scrip rose 0.68% to currently trade at Rs 543.65 on the BSE.
|